Computer simulation of randomized cancer screening trials to compare methods of estimating lead time and benefit time

Computational Statistics and Data Analysis

Volumn 23, Issue 2, 1996, Pages 263-291

  Kafadar, Karen ^a   Prorok, Philip C ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bivariate gamma density; Catch up point; Disease progression model; Incidence rate; Sojourn time; Survival time; Test sensitivity

Indexed keywords

COMPUTER SIMULATION; MATHEMATICAL MODELS; PARAMETER ESTIMATION; PROBABILITY; RANDOM PROCESSES;

BENEFIT TIME; BIVARIATE GAMMA DENSITY; CATCH UP POINT; DISEASE PROGRESSION MODEL; INCIDENCE RATE; LEAD TIME; SCREENING TRIALS; SOJOURN TIME; SURVIVAL TIME; TEST SENSITIVITY;

STATISTICAL TESTS;

EID: 0030392096     PISSN: 01679473     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-9473(96)00029-1     Document Type: Article

References (30)

1. Albert, A., P.M. Gertman and T. Louis, Screening for the early detection of cancer I: The temporal natural history of a progressive disease state, Math. Biosci., 40 (1978) 1-59.
2. Byar, D.P., R.M. Simon, W.T. Friedewald, J.J. Schlesselman, D.L. DeMets, J.H. Ellenberg, M.H. Gail and J.H. Ware, Randomized clinical trials: Perspectives on some recent ideas, New England J. Medicine, 295 (1976) 74-80.
3. Chen, J. and P.C. Prorok, An age dependent stochastic model of periodic screening: Basic properties, Math. Biosci., 65 (1983) 69-91.
4. Chen, J., P.C. Prorok and K.M. Graff, An age dependent stochastic model of periodic screening: Length bias at a prevalence screen, Math. Biosci., 65 (1983) 93-123.
5. Day, N.E. and S.D. Walter, Simplified models of screening for chronic disease: Estimation procedures from mass screening programmes, Biometrics, 40 (1984) 1-14.
6. Ellenberg, J., Selection bias in observational and experimental studies, Statist. Medicine, 13 (1994) 557-567.
7. Efron, B., The jackknife, the bootstrap and other resampling plans (Society for Industrial and Applied Mathematics, Philadelphia, 1982).
8. Flanders, W.D. and I.M. Longini Jr., Estimating benefits of screening from observational cohort studies, Statist. Medicine, 9 (1990) 969-980.
9. Fontana, R.S., D.R. Sanderson, L.B. Woolner, W.F. Taylor, W.E. Miller, J.R. Muhm, P.E. Bernatz, W.S. Payne, P.C. Pairolero and E.J. Bergstalh, Screening for lung cancer: A critique of the Mayo lung project, Cancer, 67 (1991) 1155-1164.
10. Gail, M.H., Measuring the benefit of reduced exposure to environmental carcinogens, J. Chronic Diseases, 28 (1975) 135-147.
11. Gohagen, J.K., P.C. Prorok, B.S. Kramer and J.E. Cornett, Prostate cancer screening in the prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute, J. Urology, 152 (1994) 1905-1909.
12. Habbema, J.D.F., G.J. Van Oortmarssen and D.J. Van Putten, An analysis of survival differences between clinically and screen-detected cancer patients, Statist. Medicine, 2 (1983) 279-183.
13. Huber, P.J., Robust statistics (Wiley, New York, 1981).
14. Hutchinson, G.B. and S. Shapiro, Lead time gained by diagnostic screening for breast cancer, J. National Cancer Inst., 41 (1968) 665-681.
15. IMSL, Inc. User's manual: IMSL stat/library (IMSL: Sugar Land, Texas, 1992).
16. Kafadar, K. and P. Prorok, A Data-Analytic Approach for Estimating Lead Time and Screening Benefit Based on Survival Curves in Randomized Trials, Statist. Medicine, 13 (1994) 569-586.
17. Kafadar, K., P.C. Prorok and P.J. Smith, An estimate of the variance of estimators for lead time and screening benefit in randomized cancer screening trials, submitted.
18. Lehmann, E.L., Testing statistical hypotheses, 2nd edn. (Wiley, New York, 1986).
19. Morrison, A., The effects of early treatments, lead time, and length bias on the mortality experienced by cases detected by screening, Internat. J. Epidemiology, 11 (1982) 261-267.
20. Morrison, A., Screening for chronic diseases (Oxford University Press, Oxford, 1992).
21. Prorok, P.C., The theory of periodic screening. I: Lead time and proportion detected, Adv. Appl. Probab., 8 (1976) 127-143.
22. Prorok, P.C. (1984), Evaluation of screening programs for the early detection of cancer, in: R.G. Cornell (Ed.) Statistical methods for cancer studies (Marcel Dekker, New York, 1984) Ch. 7, 267-328.
23. Prorok, P.C. and R.J. Connor, Screening for the early detection of cancer, Cancer Investigation, 4(3) (1986) 225-238.
24. Shapiro, S., W. Venet, P. Strax and L. Venet, Periodic screening for breast cancer: the health insurance plan project and its sequelae, 1963-1986 (Johns Hopkins University Press, Baltimore, 1988).
25. Spratt, J.S., J.S. Meyer and J.A. Spratt, Rates of growth of human solid neoplasms, Part I, J. Surgical Oncology, 60 (1995) 137-146.
26. Spratt, J.S., J.S. Meyer and J.A. Spratt, Rates of growth of human neoplasms, Part II, J. Surgical Oncology, 61 (1996) 68-83.
27. Statistical Sciences Inc., S-Plus user's manual, version 3.0 (Seattle, Washington, 1991).
28. Timmel, M. J., A model to estimate the false negative rate, mean sojourn time, and mean lead time in cancer screening studies, Master's thesis (University of Maryland, College Park, Maryland, 1992).
29. Walter, S.D. and N.E. Day, Estimation of the duration of a preclinical state using screening data, Amer. J. Epidemiology, 118 (1983) 865-886.
30. Zelen, M. and M. Feinleib, On the theory of screening for chronic diseases, Biometrika, 56 (1969) 601-613.